# The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

> **NCT03652467** · PHASE1 · UNKNOWN · sponsor: **Jinan Military General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **DRUG:** Conventional TACE
- **DRUG:** Deferoxamine and conventional TACE

## Key facts

- **NCT ID:** NCT03652467
- **Lead sponsor:** Jinan Military General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03652467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03652467, "The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03652467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*